UK shareholder meetings calendar - next 7 days
6th May 2025 14:14
(Alliance News) - The following stocks are the leading risers and fallers on AIM on Tuesday. Read More
(Alliance News) - London's FTSE 100 opened higher on Tuesday following the long Easter weekend, as the gold price rallies in response to a weakening US dollar and efforts by US President Donald Trump to potentially force out the Federal Reserve chair. Read More
(Alliance News) - Hutchmed China Ltd on Tuesday said it has completed patient enrolment for a phase II registration trial of savolitinib, targeting gastric cancer in patients with MET gene amplification. Read More
(Alliance News) - London's FTSE 100 was called higher on Tuesday following the long Easter weekend as the gold price reaches a new record high, while US investors remain cautious amid US President Donald Trump's threats to oust the Federal Reserve chair. Read More
Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - The new drug application for Tazverik has been granted conditional approval by the National Medical Products Administration in China for the treatment of adult patients with relapsed or refractory follicular lymphoma with the EZH2 gene mutation who have received at least two prior systemic therapies. Approval was based on positive results from a phase II bridging study in China, and clinical studies conducted by Epizyme Inc, a subsidiary of Paris-based pharmaceutical firm Ipsen SA. Read More
Hutchmed China Ltd - Hong Kong-based biopharmaceutical firm - Results from the Savannah phase 2 trial showed savolitinib plus Tagrisso achieved a clinically meaningful and durable objective response rate in patients with epidermal growth factor receptor mutated non-small cell lung cancer with high levels of MET overexpression and/or amplification, whose disease progressed on treatment with first line Tagrisso. MET refers to abnormal production of a receptor tyrosine kinase, beyond its normal levels, and is associated with tumour growth and progression. Hutchmed will present new and updated data from several studies in Paris at the European Lung Cancer Congress, which will take place between next week Wednesday and March 29. Tagrisso is a drug made by AstraZeneca PLC. Read More
(Alliance News) - Hutchmed China Ltd on Wednesday hailed results of a clinical trial evaluating its kidney cancer treatment in China, while it reported an annual revenue dive. Read More
Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Says its lung cancer treatment Orpathys has received full approval in China for adult patients. It has been developed in collaboration with AstraZeneca PLC, with Hutchmed leading in China and AZ leading outside of China. The drug was approved by the China National Medical Products Administration for the treatment of adult patients with locally advanced or metastatic non-small cell lung cancer. The approval was based on data from the confirmatory phase 3B clinical trial. Read More
(Alliance News) - Stock prices in London opened higher on Tuesday ahead of important US producer price inflation data due this afternoon. Read More
(Alliance News) - Hutchmed (China) Ltd on Thursday said it has agreed to divest a 45% stake in Shanghai Hutchison Pharmaceuticals Ltd to GP Health Service Capital Co Ltd and Shanghai Pharmaceuticals Holding Co Ltd, for a total of around USD608 million. Read More
(Alliance News) - London's FTSE 100 is set to open the year in the green, with a series of manufacturing purchasing managers' index readings the first hurdle for equities in 2025. Read More
Hutchmed (China) Ltd - Hong Kong-based biopharmaceutical firm - Is to receive a USD10 million milestone payment from partner Takeda Pharmaceutical Co Ltd. Takeda receives a national reimbursement recommendation for the Fruzaqla cancer treatment in Spain this month. It is the first national reimbursement recommendation in Europe for the drug. "We are delighted for both our partner, Takeda, and patients in Spain who will now be able to receive reimbursement for this innovative treatment. This is an important step forward in improving patient access across Europe more broadly," Hutchmed Chief Executive Officer Weiguo Su says. "It also underscores our ongoing collaboration with Takeda and reinforces our shared commitment to addressing the needs of patients with metastatic colorectal cancer." Read More
(Alliance News) - London's FTSE 100 is called to open higher on Friday, shaking off poor UK data, a sharp decline in Asian equities, and weaker trade in the US overnight. Read More
(Alliance News) - Hutchmed China Ltd on Tuesday reported it was granted conditional approval in China for an injection to treat endometrial cancer. Read More
(Alliance News) - Hutchmed (China) Ltd on Friday said it will receive a milestone payment from Takeda Pharmaceutical Co Ltd after Takeda launched Hutchmed's Fruzaqla in Japan. Read More
(Alliance News) - Hutchmed (China) Ltd on Thursday said it will receive a USD20 million payment from its partner Takeda Pharmaceutical Co Ltd which achieved a net sales milestone. Read More
(Alliance News) - Hutchmed China Ltd on Wednesday said that Tagrisso plus Orpathys showed a high clinically meaningful response rate in patients with a form of lung cancer. Read More